InnoSer

🌍 Today is #WorldPsoriasisDay – a reminder of the millions who live with this chronic autoimmune condition and the need for continued advancements in treatment options. At InnoSer, we’re proud to contribute to this mission by offering preclinical research services essential for the study and development of novel psoriasis therapies. Our IL-23 induced research model has become an invaluable tool in advancing our understanding of psoriasis, providing insights into the mechanisms that drive inflammation and skin pathology. Read more about how you can utilize this model in your research here: https://lnkd.in/eT3QZmp9. #WorldPsoriasisDay #PsoriasisResearch #PreclinicalResearch #CRO #InnoSer #LifeSciences #IL23Model #AutoimmuneResearch

We are excited to announce that InnoSer will be attending #BioEurope2024 from November 4-6 in Stockholm, Sweden! At InnoSer, we specialize in providing high-quality preclinical research services, accelerating the path from discovery to clinical trials. Our innovative solutions cover a broad spectrum of general drug development services (early-stage toxicology, biodistribution, PK/PD profiling, etc.,), including efficacy studies in oncology, neurodegenerative disease models, and much more. Our delegates will be on-site to meet and discuss how InnoSer can help drive your projects forward with tailored preclinical solutions. 💡 Meet our experts at the Belgian booth: - Amandine Boeckx - Charlotte Wuyts Don't miss the opportunity to connect with our team! Schedule a meeting in advance to explore how we can collaborate via Bio-Europe's own partnering platform or our website: https://lnkd.in/eHH4bmZT See you in Stockholm! 🇸🇪 #BioEurope #PreclinicalCRO #InnoSer #DrugDevelopment #Biotech #Pharma #LifeSciences #ResearchInnovation #PartneringConference

💊 In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. 🧫 In our latest blog post, we showcase an example of a cost-effective in vitro PD-1 PD-L1 blockade assay that can be utilized to obtain quick, but essential MoA and potency in vitro data prior to progressing to in vivo animal pharmacology, toxicology and/or efficacy studies. In this blog post we discuss: 👉 Key applications of the PD-1 PD-L1 blockade assay 👉 PD-1 PD-L1 blockade assay principles Continue reading the blog post here: https://lnkd.in/em3_ufp2 #OncologyCRO #ImmuneCheckpointInhibition #PD1PDL1blockadeassay #EuropeanOncologyCRO #InVitroImmunoOncologyAssays

📸 Hello from our team, Amandine Boeckx and Jolien B. from #ESGCT taking place in beautiful Rome! 🧬 Are you attending #ESGCT? Let's connect and explore how we can collaborate to drive innovation in the groundbreaking space of cell and gene therapies. 👉 Schedule a meeting with our team now: https://lnkd.in/eHH4bmZT. #ESGCTCongress2024 #ESGCT2024 #CellTherapy #GeneTherapy #PreclinicalResearch #CRO #PharmacologyCRO

🎗️ October represents #BreastCancerAwarenessMonth. This month we're joining forces to highlight the fight against breast cancer, raising awareness and the importance of innovative research in finding a cure. At InnoSer, we're proud to support preclinical oncology research with advanced models (ranging from in vitro, syngeneic to patient-derived xenograft models) that facilitate testing of novel treatments against breast cancer. Our team collaborates with researchers to accelerate drug development, utilizing gold-standard models such as 4T1. To learn more, please feel free to visit our website and view our 4T1 model (available at InnoSer both as subcutaneous and orthotopic using 4T1-luc transduced line allowing for longitudinal BLI measures) sample data: https://lnkd.in/eND8a3WW. 

Diepenbeek, Belgium, October 16th, 2024 — InnoSer, a leading preclinical contract research organization (CRO), announces the signing of a Memorandum of Understanding (MoU) with BIOMED-UHasselt, a multidisciplinary research institute part of Hasselt University. The signing of this agreement marks a significant initiative aimed at advancing therapeutic development by offering well-characterized cellular and animal models for Multiple Sclerosis research. Continue reading here: https://lnkd.in/e5nD3d5G

Our team members, Amandine Boeckx and Charlotte Wuyts, are excited to be exhibiting at the Advanced Therapies in Belgium event today, connecting with local innovators in the field of advanced therapies. As a preclinical CRO based in Belgium and the Netherlands, we’re proud to support local and international breakthroughs! 🧬 Come by our booth to explore how we can accelerate your drug development journey! Let’s drive innovation together. 🚀 #ATMP #CRO #PreclinicalResearchCRO #EuropeanCRO #AdvancedTherapies #GeneTherapy #CellTherapy #AdvancedTherapyMedicinalProducts #DrugDevelopmentCRO

InnoSer is Heading to #ESGCT 2024! 🌍 We are thrilled to announce that InnoSer will be attending the upcoming #ESGCTCongress2024 in Rome where leaders and innovators in the field of cell and gene therapy will gather to share their knowledge and breakthroughs. Our team, including our Director of Business Development and Immuno-Oncology, Amandine Boeckx, and Study Director of Pharmacology and Neurology, Jolien B., will be present to discuss how our innovative preclinical services can support the development of your transformative cell and gene therapies. 💡 🔬 At InnoSer, we specialize in delivering innovative preclinical models in the rare genetic and immuno-oncology field as well advanced in vivo pharmacology solutions, designed to accelerate your therapeutic pipeline from concept to clinic. 👉 Let's connect and explore how we can collaborate to drive innovation in this groundbreaking space! If you're attending ESGCT or would like to schedule a meeting, feel free to reach out to our team: https://lnkd.in/eHH4bmZT. 🧬 We look forward to seeing you there and sharing insights into the future of gene and cell therapies! #ESGCT2024 #CellTherapy #GeneTherapy #PreclinicalResearch #CRO #PharmacologyCRO

This week marked the #StemCellAwarenessWeek 🧫 Stem cells are cells that are capable of differentiation into multiple different and specialized cell lines (think muscle, brain, or skin cells) as well as self-renewal. Because of this, stem cells hold great therapeutic potential for applications in regenerative and rare disease medicine. However, novel stem cell therapies need to be thoroughly evaluated in preclinical research phases before being tested and administered in human clinical trials. Due to their nature, stem cells have potential oncologic properties that need to be addressed by performing for e.g., tumorigenicity studies. InnoSer has experience in performing both biodistribution and tumorigenicity studies using novel (stem) cell therapy approaches. Contact us to learn more about this type of service that InnoSer can offer you: https://lnkd.in/eHH4bmZT. #StemCellAwarenessDay #StemCellSolutions #EuropeanCRO

We are thrilled to announce our participation and sponsorship of the upcoming Advanced Therapies in Belgium! This event will bring together industry experts, researchers, and professionals to discuss the latest innovations and regulatory advancements in the ATMP field. 📅 Date: 15th of October 🕒 Time: 09:00-19:00 📍 Location: Business Village Ecolys, Namur, Belgium At InnoSer, we believe in the power of collaboration and knowledge sharing. This event is a fantastic opportunity to connect, share insights, and explore how we can collectively drive the future of advanced therapies. We would love to see you at our booth! Let’s advance the ATMP landscape together! 🙌 👉 Contact our business development team Amandine Boeckx and Charlotte Wuyts to schedule an onsite meeting now: https://lnkd.in/eHH4bmZT #ATMP #AdvancedTherapies #InnoSer #Networking #HealthcareInnovation #CRO #EuropeanCRO #PreclinicalCRO